Cannabinoid Receptor Modulators for Alcohol Abuse Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alcohol abuse and dependence are inadequate due to non-compliance and potential hepatotoxicity, and there is a need for safer and more effective therapeutic options for conditions modulated by cannabinoid receptors, such as pain and obesity.
Innovation Solution
Development of cannabinoid receptor modulators, specifically compounds of the formula and their analogs, which can act as CB1 or CB2 receptor agonists or antagonists to treat alcohol abuse and other disorders without the hepatotoxicity associated with existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for alcohol abuse are used, then therapeutic effect is achieved, but hepatotoxicity occurs
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with modified molecular structures (formula I with specific substituents R1-R6) that alter the pharmacological parameters of cannabinoid receptor interaction. These structural modifications enable the compounds to achieve therapeutic effects while reducing hepatotoxicity by changing how the substance interacts with biological systems, specifically targeting CB1 and CB2 receptors with improved safety profiles.
2Reliability
If anandamide is used to activate CB1 receptors, then presynaptic inhibition is achieved, but rapid enzymatic hydrolysis occurs
Solution Approach 1:
The patent applies this principle by designing synthetic cannabinoid compounds that, while structurally complex, are designed for single-use therapeutic administration. These compounds provide sufficient duration of action for therapeutic effect without requiring long-term stability in the gastrointestinal tract, as they are administered systemically rather than orally in a way that requires GI persistence. The compounds achieve their purpose in a single therapeutic dose.
Solution Approach 2:
The patent applies composite materials by creating complex molecular structures that combine multiple functional groups (amino, carbonyl, hydroxyl, and various substituted phenyl groups) within a single cannabinoid compound. This composite molecular architecture provides both the necessary receptor binding affinity for CB1/CB2 activation and improved metabolic stability compared to natural anandamide, resolving the contradiction between activity and stability.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CBl) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).